Experimental group:Surufatinib

3 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Anqing Hospital of the PLA Navy, Liaoning Cancer Hospital & institute

Conditions

Biliary tract cancerSmall cell lung cancergastrointestinal tumors

Phase 2

The efficacy and safety of Surufatinib in patients with previously treated small cell lung cancer: A Phase II Study(Single-arm, Open-label, Single-Center)

RecruitingChiCTR2300071990

Liaoning Cancer Hospital & instituteSmall cell lung cancer

Start: 2022-07-11Updated: 2023-06-12

Phase 4

A single-arm, open-label, single-center clinical study of surufatinib in the second-line treatment of patients with unresectable or metastatic biliary tract cancer

Active, not recruitingChiCTR2100052782

Tianjin Medical University Cancer Institute and HospitalBiliary tract cancer

Start: 2022-02-01Updated: 2023-04-12

An observational clinical study of the safety and efficacy of Surufatinib in advanced gastrointestinal tumors

Active, not recruitingChiCTR2200057717

Anqing Hospital of the PLA Navygastrointestinal tumors

Start: 2022-03-01Updated: 2023-11-06